The Food and Drug Administration and pharmaceutical giant Merck have agreed on a "special protocol assessment" that will determine if the cancer drug oral deforolimus for patients with cancer of the body's connective tissue(s).


Merck and partner Ariad will begin patient enrollment for deforolimus later in September, with progression-free survival being the endpoint of the Phase III trial. The second endpoint? How about overall patient survival?

Since there are currently very few effective treatments for sarcoma cancers, my bet is that this new drug will be on the market the date the Phase III trial officially concludes.



The main source for this article is TheCancerBlog